AU2014279113B2 - 4-alkynyl imidazole derivative and medicine comprising same as active ingredient - Google Patents
4-alkynyl imidazole derivative and medicine comprising same as active ingredient Download PDFInfo
- Publication number
- AU2014279113B2 AU2014279113B2 AU2014279113A AU2014279113A AU2014279113B2 AU 2014279113 B2 AU2014279113 B2 AU 2014279113B2 AU 2014279113 A AU2014279113 A AU 2014279113A AU 2014279113 A AU2014279113 A AU 2014279113A AU 2014279113 B2 AU2014279113 B2 AU 2014279113B2
- Authority
- AU
- Australia
- Prior art keywords
- group
- mmol
- compound
- methyl
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C)(C#CC(C)=C(C(O)=O)N(Cc1ccc(C)cc1)C(Cl)=CC*)O Chemical compound CC(C)(C#CC(C)=C(C(O)=O)N(Cc1ccc(C)cc1)C(Cl)=CC*)O 0.000 description 5
- ADZVHZWDQGGXML-UHFFFAOYSA-N CC(C)(C#CC1=C(C(NCC(CC2)CCC2C(OC)=O)=O)N(Cc2ccc(C(F)(F)F)cc2)C(Cl)=CC=C1)O Chemical compound CC(C)(C#CC1=C(C(NCC(CC2)CCC2C(OC)=O)=O)N(Cc2ccc(C(F)(F)F)cc2)C(Cl)=CC=C1)O ADZVHZWDQGGXML-UHFFFAOYSA-N 0.000 description 1
- IFXDWRWHABFITR-UHFFFAOYSA-N CC(C)(C#Cc1c(C(NC2(CC2)c(cc2)ccc2C(O)=O)=O)[n](Cc2ccc(C)cc2)c(Cl)n1)OC Chemical compound CC(C)(C#Cc1c(C(NC2(CC2)c(cc2)ccc2C(O)=O)=O)[n](Cc2ccc(C)cc2)c(Cl)n1)OC IFXDWRWHABFITR-UHFFFAOYSA-N 0.000 description 1
- DMKZRTFMGGQASS-UHFFFAOYSA-N CC(C)(C#Cc1c(C(NC2(CC2)c(cc2)ccc2C(OC)=O)=O)[n](Cc2ccc(C)cc2)c(Cl)n1)OC Chemical compound CC(C)(C#Cc1c(C(NC2(CC2)c(cc2)ccc2C(OC)=O)=O)[n](Cc2ccc(C)cc2)c(Cl)n1)OC DMKZRTFMGGQASS-UHFFFAOYSA-N 0.000 description 1
- RCRVNFOIGXSYOT-UHFFFAOYSA-N CC(C)(C#Cc1c(C(NCC2CCCCC2)=O)[n](Cc2ccc(C)cc2)c(Cl)n1)OC Chemical compound CC(C)(C#Cc1c(C(NCC2CCCCC2)=O)[n](Cc2ccc(C)cc2)c(Cl)n1)OC RCRVNFOIGXSYOT-UHFFFAOYSA-N 0.000 description 1
- HKNFHDLPUXTCQE-UHFFFAOYSA-N CC(C)(C)OC(NCc(cc1)ccc1C(N1)=NOC1=O)=O Chemical compound CC(C)(C)OC(NCc(cc1)ccc1C(N1)=NOC1=O)=O HKNFHDLPUXTCQE-UHFFFAOYSA-N 0.000 description 1
- HUSVWSFUZISZRY-UHFFFAOYSA-N CC(C)(CO)C#Cc1c(C(NCC(CC2)CCC2N)=O)[n](CCOc(cc2)ccc2Cl)c(Cl)n1 Chemical compound CC(C)(CO)C#Cc1c(C(NCC(CC2)CCC2N)=O)[n](CCOc(cc2)ccc2Cl)c(Cl)n1 HUSVWSFUZISZRY-UHFFFAOYSA-N 0.000 description 1
- ZZNVBHMFMUVGHK-UHFFFAOYSA-N CC(CC=C)C(F)(F)F Chemical compound CC(CC=C)C(F)(F)F ZZNVBHMFMUVGHK-UHFFFAOYSA-N 0.000 description 1
- UYBJHVSZRXMCIQ-UHFFFAOYSA-N CC(NCC1CCCCC1)=O Chemical compound CC(NCC1CCCCC1)=O UYBJHVSZRXMCIQ-UHFFFAOYSA-N 0.000 description 1
- XVCMLNJYQSBFPR-UHFFFAOYSA-N N#Cc1ccc(CI)cc1 Chemical compound N#Cc1ccc(CI)cc1 XVCMLNJYQSBFPR-UHFFFAOYSA-N 0.000 description 1
- XRDQEUKSKIDNGB-UHFFFAOYSA-N NCc(cc1)ccc1C(N1)=NOC1=O Chemical compound NCc(cc1)ccc1C(N1)=NOC1=O XRDQEUKSKIDNGB-UHFFFAOYSA-N 0.000 description 1
- AVKNGPAMCBSNSO-UHFFFAOYSA-O [NH3+]CC1CCCCC1 Chemical compound [NH3+]CC1CCCCC1 AVKNGPAMCBSNSO-UHFFFAOYSA-O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013123968 | 2013-06-12 | ||
| JP2013-123968 | 2013-06-12 | ||
| PCT/JP2014/065643 WO2014200075A1 (ja) | 2013-06-12 | 2014-06-12 | ４－アルキニルイミダゾール誘導体およびそれを有効成分として含有する医薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014279113A1 AU2014279113A1 (en) | 2016-01-21 |
| AU2014279113B2 true AU2014279113B2 (en) | 2018-04-12 |
Family
ID=52022361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014279113A Active AU2014279113B2 (en) | 2013-06-12 | 2014-06-12 | 4-alkynyl imidazole derivative and medicine comprising same as active ingredient |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US9593081B2 (enExample) |
| EP (1) | EP3009426B1 (enExample) |
| JP (1) | JP6276760B2 (enExample) |
| KR (1) | KR102212981B1 (enExample) |
| CN (1) | CN105431416B (enExample) |
| AU (1) | AU2014279113B2 (enExample) |
| BR (1) | BR112015030315B1 (enExample) |
| CA (1) | CA2914997C (enExample) |
| DK (1) | DK3009426T3 (enExample) |
| ES (1) | ES2669977T3 (enExample) |
| HR (1) | HRP20180703T1 (enExample) |
| HU (1) | HUE039015T2 (enExample) |
| IL (1) | IL242912A0 (enExample) |
| LT (1) | LT3009426T (enExample) |
| MX (1) | MX369804B (enExample) |
| MY (1) | MY168609A (enExample) |
| NO (1) | NO3009426T3 (enExample) |
| NZ (1) | NZ715837A (enExample) |
| PH (1) | PH12015502745B1 (enExample) |
| PL (1) | PL3009426T3 (enExample) |
| PT (1) | PT3009426T (enExample) |
| RS (1) | RS57406B1 (enExample) |
| RU (1) | RU2662806C2 (enExample) |
| SG (1) | SG11201510121RA (enExample) |
| SI (1) | SI3009426T1 (enExample) |
| TR (1) | TR201807659T4 (enExample) |
| WO (1) | WO2014200075A1 (enExample) |
| ZA (1) | ZA201600135B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO3009426T3 (enExample) * | 2013-06-12 | 2018-09-29 | ||
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| EP3541801A4 (en) * | 2016-11-18 | 2020-04-29 | Dow AgroSciences LLC | 4- (6- (2- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H |
| ES2887041T3 (es) | 2017-05-18 | 2021-12-21 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de PGE2 |
| EP3625223B1 (en) | 2017-05-18 | 2021-08-11 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| ES2893452T3 (es) | 2017-05-18 | 2022-02-09 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de PGE2 |
| AR111807A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2 |
| DK3625224T3 (da) | 2017-05-18 | 2021-11-08 | Idorsia Pharmaceuticals Ltd | N-substituerede indolderivater |
| US11479550B2 (en) | 2017-05-22 | 2022-10-25 | Ono Pharmaceutical Co., Ltd. | EP4 antagonist |
| JP2020142989A (ja) * | 2017-06-21 | 2020-09-10 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | イミダゾール誘導体及びそれを含有する医薬 |
| CN117643587A (zh) * | 2018-02-05 | 2024-03-05 | 深圳市原力生命科学有限公司 | 用于治疗癌症的杂二环羧酸 |
| CN108997252B (zh) * | 2018-07-27 | 2020-04-28 | 常州大学 | 一种恶二唑衍生物的绿色合成方法 |
| US20230390303A1 (en) | 2020-11-13 | 2023-12-07 | Ono Pharmaceutical Co., Ltd. | Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012039972A1 (en) * | 2010-09-21 | 2012-03-29 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030072614A (ko) * | 2001-01-31 | 2003-09-15 | 화이자 프로덕츠 인크. | Ｐｄｅ４ 이소자임 억제제로 유용한 티아졸릴-,옥사졸릴-, 피롤릴- 및 이미다졸릴-산 아미드 유도체 |
| WO2003016254A1 (en) | 2001-08-09 | 2003-02-27 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
| EP1506220A1 (en) | 2002-05-23 | 2005-02-16 | Theratechnologies Inc. | Antagonistic peptides of prostaglandin e2 receptor subtype ep4 |
| KR100747401B1 (ko) | 2003-09-03 | 2007-08-08 | 화이자 인코포레이티드 | 프로스타글란딘 ｅ2 길항제로서의 페닐 또는 피리딜 아미드 화합물 |
| WO2005105733A1 (en) | 2004-05-04 | 2005-11-10 | Pfizer Japan Inc. | Ortho substituted aryl or heteroaryl amide compounds |
| WO2005105732A1 (en) | 2004-05-04 | 2005-11-10 | Pfizer Japan Inc. | Substituted methyl aryl or heteroaryl amide compounds |
| AU2006215567B2 (en) * | 2005-02-16 | 2011-05-12 | Abbott Healthcare Products B.V. | 1H-imidazole derivatives as cannabinoid CB2 receptor modulators |
| ES2392192T3 (es) | 2006-04-24 | 2012-12-05 | Merck Canada Inc. | Derivados de indol amida como antagonistas del receptor EP4 |
| JP5183628B2 (ja) | 2006-06-12 | 2013-04-17 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体リガンドとしてのインドリンアミド誘導体 |
| JP5259592B2 (ja) | 2006-08-11 | 2013-08-07 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体リガンドとしてのチオフェンカルボキサミド誘導体 |
| AU2008221194B2 (en) * | 2007-02-26 | 2013-06-27 | Merck Canada Inc. | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists |
| AU2008270438B2 (en) * | 2007-07-02 | 2013-10-10 | F. Hoffmann-La Roche Ag | Imidazole derivatives as CCR2 receptor antagonists |
| WO2009005076A1 (ja) | 2007-07-03 | 2009-01-08 | Astellas Pharma Inc. | アミド化合物 |
| BRPI0912778B1 (pt) | 2008-05-14 | 2019-04-30 | Astellas Pharma Inc. | Composto de amida, composição farmacêutica compreendedo dito composto e uso do mesmo para o tratamento de insuficiência renal crônica ou nefropatia diabética |
| WO2010019796A1 (en) | 2008-08-14 | 2010-02-18 | Chemietek, Llc | Heterocyclic amide derivatives as ep4 receptor antagonists |
| CA2820109C (en) | 2010-12-10 | 2018-01-09 | Rottapharm S.P.A. | Pyridine amide derivatives as ep4 receptor antagonists |
| WO2012103071A2 (en) | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Compounds and compositions |
| KR101760164B1 (ko) | 2011-07-04 | 2017-07-20 | 로타팜 바이오테크 에스.알.엘 | Ep4 수용체 길항제로서 사이클릭 아민 유도체 |
| NO3009426T3 (enExample) * | 2013-06-12 | 2018-09-29 |
-
2014
- 2014-06-12 NO NO14811154A patent/NO3009426T3/no unknown
- 2014-06-12 ES ES14811154.5T patent/ES2669977T3/es active Active
- 2014-06-12 TR TR2018/07659T patent/TR201807659T4/tr unknown
- 2014-06-12 EP EP14811154.5A patent/EP3009426B1/en active Active
- 2014-06-12 BR BR112015030315-3A patent/BR112015030315B1/pt active IP Right Grant
- 2014-06-12 NZ NZ715837A patent/NZ715837A/en unknown
- 2014-06-12 MY MYPI2015704535A patent/MY168609A/en unknown
- 2014-06-12 WO PCT/JP2014/065643 patent/WO2014200075A1/ja not_active Ceased
- 2014-06-12 AU AU2014279113A patent/AU2014279113B2/en active Active
- 2014-06-12 CN CN201480044505.6A patent/CN105431416B/zh active Active
- 2014-06-12 SI SI201430707T patent/SI3009426T1/en unknown
- 2014-06-12 CA CA2914997A patent/CA2914997C/en active Active
- 2014-06-12 MX MX2015017161A patent/MX369804B/es active IP Right Grant
- 2014-06-12 LT LTEP14811154.5T patent/LT3009426T/lt unknown
- 2014-06-12 JP JP2015522867A patent/JP6276760B2/ja active Active
- 2014-06-12 HU HUE14811154A patent/HUE039015T2/hu unknown
- 2014-06-12 PL PL14811154T patent/PL3009426T3/pl unknown
- 2014-06-12 PT PT148111545T patent/PT3009426T/pt unknown
- 2014-06-12 US US14/897,324 patent/US9593081B2/en active Active
- 2014-06-12 DK DK14811154.5T patent/DK3009426T3/en active
- 2014-06-12 SG SG11201510121RA patent/SG11201510121RA/en unknown
- 2014-06-12 RS RS20180743A patent/RS57406B1/sr unknown
- 2014-06-12 KR KR1020167000476A patent/KR102212981B1/ko active Active
- 2014-06-12 HR HRP20180703TT patent/HRP20180703T1/hr unknown
- 2014-06-12 RU RU2015155585A patent/RU2662806C2/ru active
-
2015
- 2015-12-03 IL IL242912A patent/IL242912A0/en active IP Right Grant
- 2015-12-09 PH PH12015502745A patent/PH12015502745B1/en unknown
-
2016
- 2016-01-07 ZA ZA2016/00135A patent/ZA201600135B/en unknown
-
2017
- 2017-01-24 US US15/414,200 patent/US9855257B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012039972A1 (en) * | 2010-09-21 | 2012-03-29 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014279113B2 (en) | 4-alkynyl imidazole derivative and medicine comprising same as active ingredient | |
| RU2518073C2 (ru) | Новое бициклическое гетероциклическое соединение | |
| WO2011099832A2 (en) | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same | |
| CA2870336A1 (en) | Cyclic bridgehead ether dgat1 inhibitors | |
| AU2018212473B2 (en) | Amide compounds and use thereof | |
| AU2017213993B2 (en) | Heterocyclic sulfonamide derivative and medicine containing same | |
| EP3334727A1 (en) | Pyridine and pyrimidine derivatives | |
| AU2013366974B2 (en) | Cinnamic acid amide derivative | |
| WO2017060202A1 (en) | Triazole derivatives | |
| AU2020364118B2 (en) | Prostaglandin EP4 receptor antagonist compounds | |
| WO2011024468A1 (ja) | 新規なスルホンアミド誘導体及びこれを含有する医薬 | |
| KR20200022710A (ko) | Ｔ-형 칼슘 채널에 활성을 가지는 피롤리딘 또는 피페리딘 화합물 | |
| HK1221215B (zh) | 4-炔基咪唑衍生物和含有其作为有效成分的药物 | |
| WO2019022234A1 (ja) | 炎症性腸疾患の治療剤又は予防剤 | |
| TW201111364A (en) | Renin inhibitors | |
| GB2516818A (en) | Antiviral drug derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |